The meeting will start promptly at 10:00 and is expected to finish at approximately 15:00
Please note that this agenda is subject to change prior to the meeting.
1. Welcome and introduction to format of meeting - Part 1 only (open session)
2. Apologies - Part 1 only (open session)
3. Any other business - Part 1 only (open session)
4. Minutes from the last Committee meeting held on 27 January 2016 - Part 1 only (open session)
5. Appraisal of Lumacaftor and ivacaftor combination therapy for treating cystic fibrosis homozygous for the F508del mutation
5.1 Declarations of interest - Part 1 only (open session)
5.2 Introduction by the Chair, Professor Gary McVeigh - Part 1 only (open session)
5.3 Presentation by the Lead team, Dr Matthew Bradley, Mrs Tracey Cole and Professor Gary McVeigh - Part 1 AND part 2 (open and closed session)
5.4 Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) - Part 2 only (closed session)
Date, time and venue of next meeting:
Wednesday 23 March 2016 10:00am, NICE, Level 1, City Tower, Piccadilly Plaza, Manchester, M1 4BT.
Please note all timings are approximate.
To print the agenda, please right click and select 'Print' from the menu
You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
The closing date for registration is 11 February 2016. Please note that it may not be possible to accept late registration requests
Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Lee Berry
Please note that registrants wishing to conduct a research study on the committee meeting and/or NICE processes will require prior permission and should contact NICE Enquiry Handling by email firstname.lastname@example.org
Further information about conducting research is also available in our Common Questions and Answers about meetings in public document